Search Results for: PTPRC

Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
LSM1 LSM1 homolog, mRNA degradation associated
  • mRNA decay by 5' to 3' exoribonuclease
  • mRNA decay by 5' to 3' exoribonuclease
LYN LYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Fc epsilon receptor (FCERI) signaling
  • Fc epsilon receptor (FCERI) signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated NF-kB activation
  • Co-stimulation by CD28
  • Co-inhibition by CTLA4
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • CD22 mediated BCR regulation
  • Cyclin D associated events in G1
  • Platelet Adhesion to exposed collagen
  • Signaling by Erythropoietin
  • Signaling by Erythropoietin
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Bosutinib
  • Ponatinib
  • Nintedanib
  • Fostamatinib
MAPK1 mitogen-activated protein kinase 1
  • phospho-PLA2 pathway
  • RAF-independent MAPK1/3 activation
  • MAPK1 (ERK2) activation
  • Signaling by NODAL
  • Spry regulation of FGF signaling
  • Signaling by Activin
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Frs2-mediated activation
  • ERK/MAPK targets
  • ERK/MAPK targets
  • ERKs are inactivated
  • Regulation of actin dynamics for phagocytic cup formation
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Oncogene Induced Senescence
  • FCERI mediated MAPK activation
  • Regulation of HSF1-mediated heat shock response
  • NCAM signaling for neurite out-growth
  • Recycling pathway of L1
  • RSK activation
  • Signal transduction by L1
  • Activation of the AP-1 family of transcription factors
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate NADPH Oxidases
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Neutrophil degranulation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signal attenuation
  • Interferon gamma signaling
  • Advanced glycosylation endproduct receptor signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • ESR-mediated signaling
  • RUNX2 regulates osteoblast differentiation
  • Regulation of PTEN gene transcription
  • Regulation of the apoptosome activity
  • Estrogen-stimulated signaling through PRKCZ
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Suppression of apoptosis
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by MAPK mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • Nuclear events stimulated by ALK signaling in cancer
  • IFNG signaling activates MAPKs
  • Negative Regulation of CDH1 Gene Transcription
  • NPAS4 regulates expression of target genes
  • NPAS4 regulates expression of target genes
  • Growth hormone receptor signaling
  • Signaling by LTK in cancer
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Acetylsalicylic acid
  • Minocycline
  • Arsenic trioxide
  • Olomoucine
  • Phosphonothreonine
  • Colforsin
  • Purvalanol
  • SB220025
  • Seliciclib
  • Perifosine
  • N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
  • (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
  • 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
  • Hypothemycin
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • Turpentine
  • Ulixertinib
MBL2 mannose binding lectin 2
  • Lectin pathway of complement activation
  • Initial triggering of complement
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • O3-Sulfonylgalactose
  • Methyl alpha-D-mannoside
  • 4-(Hydrogen sulfate)-beta-D-galactopyranose
  • Methyl beta-L-fucopyranoside
  • N-acetyl-alpha-neuraminic acid
  • alpha-L-methyl-fucose
  • Alpha-Methyl-N-Acetyl-D-Glucosamine
  • Tuberculosis
  • Mannose-binding lectin pathway component defects, including the following two diseases: Mannose-binding lectin deficiency; Mannose-binding lectin-associated serine protease (MASP) 2 deficiency
PAEP progestagen associated endometrial protein
  • 12-Bromododecanoic Acid
  • Palmitic Acid
  • Glycerin
PPFIA1 PPFI scaffold protein A1
  • Serotonin Neurotransmitter Release Cycle
  • Norepinephrine Neurotransmitter Release Cycle
  • Glutamate Neurotransmitter Release Cycle
  • Dopamine Neurotransmitter Release Cycle
  • Acetylcholine Neurotransmitter Release Cycle
  • Receptor-type tyrosine-protein phosphatases
PPFIBP2 PPFIB scaffold protein 2
  • Receptor-type tyrosine-protein phosphatases
PRKCSH PRKCSH beta subunit of glucosidase II
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • N-glycan trimming in the ER and Calnexin/Calreticulin cycle
  • Advanced glycosylation endproduct receptor signaling
  • Post-translational protein phosphorylation
  • Calnexin/calreticulin cycle
  • Maturation of spike protein
  • Maturation of spike protein
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Polycystic liver disease
PTPN6 protein tyrosine phosphatase non-receptor type 6
  • GPVI-mediated activation cascade
  • Regulation of KIT signaling
  • Signaling by ALK
  • PECAM1 interactions
  • Co-inhibition by PD-1
  • Signal regulatory protein family interactions
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • CD22 mediated BCR regulation
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Interleukin-37 signaling
  • Interferon alpha/beta signaling
  • Interleukin receptor SHC signaling
  • Regulation of IFNA/IFNB signaling
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Nuclear events stimulated by ALK signaling in cancer
  • Growth hormone receptor signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Co-inhibition by BTLA
  • Tiludronic acid
PTPRCAP protein tyrosine phosphatase receptor type C associated protein
RASA1 RAS p21 protein activator 1
  • Downstream signal transduction
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • VEGFR2 mediated cell proliferation
  • Regulation of RAS by GAPs
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
RNF11 ring finger protein 11
SEMA4D semaphorin 4D
  • Sema4D mediated inhibition of cell attachment and migration
  • Sema4D induced cell migration and growth-cone collapse
  • Other semaphorin interactions
SKAP1 src kinase associated phosphoprotein 1
SRC SRC proto-oncogene, non-receptor tyrosine kinase
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Downregulation of ERBB4 signaling
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • Downstream signal transduction
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • G alpha (s) signalling events
  • G alpha (i) signalling events
  • G alpha (i) signalling events
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • RAF activation
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PTK2 signaling
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of RUNX1 Expression and Activity
  • RUNX2 regulates osteoblast differentiation
  • Regulation of RUNX3 expression and activity
  • Extra-nuclear estrogen signaling
  • RHOU GTPase cycle
  • Activated NTRK2 signals through FYN
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • Long-term potentiation
  • GPER1 signaling
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Degradation of CDH1
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric acid
  • Paratoulene phosphate
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • XL228
  • Tirbanibulin
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • PD-168393
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • PP-121
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Nintedanib
  • Fostamatinib
TYK2 tyrosine kinase 2
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • Other interleukin signaling
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Interleukin-20 family signaling
  • Interleukin-35 Signalling
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Interferon alpha/beta signaling
  • Regulation of IFNA/IFNB signaling
  • Regulation of IFNA/IFNB signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Potential therapeutics for SARS
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Signaling by ALK fusions and activated point mutants
  • Evasion by RSV of host interferon responses
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Fostamatinib
  • Abrocitinib
  • Deucravacitinib
  • Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
UHRF2 ubiquitin like with PHD and ring finger domains 2
  • SUMOylation of transcription cofactors
ZAP70 zeta chain of T cell receptor associated protein kinase 70
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • RHOH GTPase cycle
  • Nuclear events stimulated by ALK signaling in cancer
  • Staurosporine
  • Fostamatinib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency

Page 3 out of 3 pages